Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Keio University research: Genetics and COVID-19: New protein-link revealed for Japanese population


News provided by

Keio University

09 Sep, 2022, 05:38 GMT

Share this article

Share toX

Share this article

Share toX

TOKYO, Sept. 9, 2022 /PRNewswire/ -- In a study published recently in the journal Nature, researchers from Keio University and colleagues identify genes involved in the development of severe COVID-19 in the younger Japanese population.

This image opens in the lightbox
SNP related to COVID-19 severity was found on chromosome 5 using GWAS. ©︎ Japan COVID-19 Task Force

Genes play a key role in the development and progression of infectious diseases. While studies have identified high-risk genes for COVID-19 in Europeans, there is limited genetic data for the Japanese population. Now, an inter-Japan research collaboration has provided critical insights based on detailed genetic analysis. Koichi Fukunaga from Keio University and his colleagues show that a gene important for immune function is involved in severe COVID-19, especially in the younger Japanese population.

For their investigation, the researchers compared the genomes of 2,393 patients who suffered from COVID-19 with that of 3,289 healthy individuals. All COVID-19 patients had been hospitalized while infected and 990 of them had been afflicted by a severe form of the disease.

The researchers identified seven genes showing prominent differences between the two groups, of which six were more prevalent in younger patients (less than 65 years old) and in the more severe cases. Upon further examination of these populations, the team conducted a genetic analysis of this population revealing that the gene responsible for producing a protein called DOCK2 was mutated in these subjects.

Blood samples of COVID-19 patients were then sequenced to reveal that the risk of a mutation on this gene was associated with low levels of the DOCK2 protein. DOCK2 is currently widely understood to play a role in immune signaling, so to understand its role in the context of COVID-19 progression, the researchers isolated the blood cells of a smaller group of subjects. Their analysis showed particularly low values of DOCK2 in some white blood cells. When this observation was replicated in lab cells, using a drug that inhibits DOCK2, the cells showed hampered movement and an inability to release chemical messengers that warn the body of disease.

The worst region of the body to be affected by COVID-19 is often the lungs, often resulting in pneumonia. Therefore, lung samples of three deceased COVID-19 patients were scrutinized. DOCK2 was found to be suppressed in the cells of these samples. Finally, the team studied the real-time effects of decreased DOCK2 in hamsters infected with SARS-CoV-2. These hamsters showed greater weight loss and fluid buildup in their lungs compared to healthy ones. The migration of immune cells—which is essential in combating the virus—was also compromised in the infected hamsters.

This genome-wide study reveals the potential role of DOCK2 in influencing the severity of COVID-19, especially in younger populations. It could also be used as a target for drug development to fight the infection. "DOCK2 plays a key role in host immune response to SARS-CoV-2 infection and development of severe COVID-19, being a promising biomarker and therapeutic target,"1 concludes the team.

Reference

  1. Namkoong, H. et al. DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature (2022) doi:10.1038/s41586-022-05163-5.

Background to the research in this paper and related information

DOCK2 and the immune system: When the DOCK2 gene is activated in our cells, it passes on the green light for DOCK2 protein synthesis.

The DOCK2 protein is known to play a role in the production and release of interferons, which are chemical messengers released by infected cells to get help from distant immune cells. DOCK2 also helps certain types of white blood cells move and migrate to the site of infection (a process known as chemotaxis) to fight the invading pathogens. These mechanisms are imperative to reducing infection, and why researchers believe younger COVID-19 patients, who are at higher risk for mutations of the DOCK2 gene, showed more severe forms of the disease.

The Joint Research Coronavirus Task Force

The paper described in this press release is the culmination of recent inter-Japan collaborative research conducted by The Joint Research Coronavirus Task Force (Japan COVID-19 Task Force) comprising of more than 120 hospitals across Japan, including 13 facilities affiliated with Keio University.1 

The Japan COVID-19 Task Force was launched in May 2020 to offer a genetic approach to analyzing the spread and treatment of COVID-19.

Professor Koichi Fukunaga—lead author of the paper and specialist in respiratory medicine at the Keio University School of Medicine in Tokyo—is the head of the Task Force that has continued to collect clinical information and samples from patients during each virus variant epidemic and collaborated with hospitals throughout Japan.

The Japan COVID-19 Task Force is focusing on trends in Japan, including clarifying why the number of deaths in Japan has been significantly lower than in the United States and Europe. The results of the studies from Japanese patients are being shared with researchers worldwide to contribute to global efforts to develop treatments for COVID-19.

  1. Interview with Professor Koichi Fukunaga: "Joint Research Coronavirus Task Force: The power of integrating clinical and genetic research to understand and eliminate COVID-19"

Keio Research Highlights: https://research-highlights.keio.ac.jp/2022/01/a.html

Further information
Office of Research Development and Sponsored Projects
Keio University
2-15-45 Mita, Minato-ku, Tokyo 108-8345 Japan
Telephone: +81 (0)-3-5427-1678
E-mail: keio-rpr@adst.keio.ac.jp

Websites
Keio University
https://www.keio.ac.jp/en/

Keio Research Highlights
https://research-highlights.keio.ac.jp/

Photo: https://mma.prnewswire.com/media/1895226/fig_1.jpg

Modal title

Also from this source

Keio University Research: Genomic Insights for Personalized Cancer Treatment

In a recent paper published in Cancer Discovery, Keio University's Sara Horie and her colleagues conducted an in-depth analysis of cancer driver...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Infection Control

Infection Control

Education

Education

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.